Cytek Biosciences, Inc.
As of Oct 22, 2026, Cytek Biosciences is in Stage 2, the uptrend phase, now in week 6 (since Sep 16, 2026). It closed at $5.43, 10.8% below its 52-week high and above its 200-day average, which is rising.
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 35 in Medical Devices · #1 of 272 in Health Care
Is CTKB early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CTKB among Medical Devices26th of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
| …26 | CTKB | Stage 2 · wk 6 | 77 | −4.4% |
Cytek Biosciences: quick answers
What stage is Cytek Biosciences in?
As of Oct 22, 2026, Cytek Biosciences (CTKB) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 16, 2026 and is in week 6. What the four stages mean
Is Cytek Biosciences in an uptrend?
Yes. Cytek Biosciences is in a Stage 2 uptrend. It trades 17.0% above its 200-day average, which is rising.
How far is Cytek Biosciences from its 52-week high?
Cytek Biosciences closed at $5.43 on Oct 22, 2026, 10.8% below its 52-week high of $6.09. Its 52-week low is $3.36.
How has Cytek Biosciences performed over the past year?
As of Oct 22, 2026, Cytek Biosciences is up 30.2% over the past year and up 10.4% so far in 2026.
Which sector and industry is Cytek Biosciences in?
Cytek Biosciences is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.